vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and RadNet, Inc. (RDNT). Click either name above to swap in a different company.
RadNet, Inc. is the larger business by last-quarter revenue ($547.7M vs $281.3M, roughly 1.9× Guardant Health, Inc.). RadNet, Inc. runs the higher net margin — -0.1% vs -45.7%, a 45.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 14.8%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 12.6%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
RadNet is an American radiology firm. The company operates outpatient diagnostic imaging services. Headquartered in Los Angeles, California, RadNet is the largest operator of freestanding, fixed-site diagnostic imaging centers in the United States, based on the number of locations and annual imaging revenue. As of 2025, the company owns and/or operates over 400 imaging centers across Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas.
GH vs RDNT — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $547.7M |
| Net Profit | $-128.5M | $-597.0K |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 5.1% |
| Net Margin | -45.7% | -0.1% |
| Revenue YoY | 39.4% | 14.8% |
| Net Profit YoY | -15.8% | -111.2% |
| EPS (diluted) | $-1.01 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $547.7M | ||
| Q3 25 | $265.2M | $522.9M | ||
| Q2 25 | $232.1M | $498.2M | ||
| Q1 25 | $203.5M | $471.4M | ||
| Q4 24 | $201.8M | $477.1M | ||
| Q3 24 | $191.5M | $461.1M | ||
| Q2 24 | $177.2M | $459.7M | ||
| Q1 24 | $168.5M | $431.7M |
| Q4 25 | $-128.5M | $-597.0K | ||
| Q3 25 | $-92.7M | $5.4M | ||
| Q2 25 | $-99.9M | $14.5M | ||
| Q1 25 | $-95.2M | $-37.9M | ||
| Q4 24 | $-111.0M | $5.3M | ||
| Q3 24 | $-107.8M | $3.2M | ||
| Q2 24 | $-102.6M | $-3.0M | ||
| Q1 24 | $-115.0M | $-2.8M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 5.1% | ||
| Q3 25 | -37.3% | 5.2% | ||
| Q2 25 | -45.9% | 6.2% | ||
| Q1 25 | -54.6% | -5.1% | ||
| Q4 24 | -62.4% | 5.1% | ||
| Q3 24 | -61.3% | 7.4% | ||
| Q2 24 | -56.8% | 7.6% | ||
| Q1 24 | -59.2% | 2.6% |
| Q4 25 | -45.7% | -0.1% | ||
| Q3 25 | -35.0% | 1.0% | ||
| Q2 25 | -43.0% | 2.9% | ||
| Q1 25 | -46.8% | -8.0% | ||
| Q4 24 | -55.0% | 1.1% | ||
| Q3 24 | -56.3% | 0.7% | ||
| Q2 24 | -57.9% | -0.6% | ||
| Q1 24 | -68.2% | -0.6% |
| Q4 25 | $-1.01 | $0.00 | ||
| Q3 25 | $-0.74 | $0.07 | ||
| Q2 25 | $-0.80 | $0.19 | ||
| Q1 25 | $-0.77 | $-0.51 | ||
| Q4 24 | $-0.90 | $0.08 | ||
| Q3 24 | $-0.88 | $0.04 | ||
| Q2 24 | $-0.84 | $-0.04 | ||
| Q1 24 | $-0.94 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $767.2M |
| Total DebtLower is stronger | $1.5B | $1.1B |
| Stockholders' EquityBook value | $-99.3M | $1.1B |
| Total Assets | $2.0B | $3.8B |
| Debt / EquityLower = less leverage | — | 1.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $767.2M | ||
| Q3 25 | $580.0M | $804.7M | ||
| Q2 25 | $629.1M | $833.2M | ||
| Q1 25 | $698.6M | $717.3M | ||
| Q4 24 | $525.5M | $740.0M | ||
| Q3 24 | $585.0M | $748.9M | ||
| Q2 24 | $933.7M | $741.7M | ||
| Q1 24 | $1.0B | $527.0M |
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.1B | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $834.6M |
| Q4 25 | $-99.3M | $1.1B | ||
| Q3 25 | $-354.5M | $1.1B | ||
| Q2 25 | $-305.5M | $932.3M | ||
| Q1 25 | $-250.8M | $898.1M | ||
| Q4 24 | $-139.6M | $902.3M | ||
| Q3 24 | $-60.1M | $895.3M | ||
| Q2 24 | $-1.6M | $881.0M | ||
| Q1 24 | $68.3M | $873.0M |
| Q4 25 | $2.0B | $3.8B | ||
| Q3 25 | $1.3B | $3.7B | ||
| Q2 25 | $1.3B | $3.5B | ||
| Q1 25 | $1.3B | $3.3B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.7B | $3.0B |
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | — | 0.96× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $84.2M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $84.2M | ||
| Q3 25 | $-35.4M | $52.8M | ||
| Q2 25 | $-60.3M | $120.3M | ||
| Q1 25 | $-62.7M | $41.5M | ||
| Q4 24 | $-64.5M | $42.5M | ||
| Q3 24 | $-51.1M | $57.4M | ||
| Q2 24 | $-94.0M | $116.0M | ||
| Q1 24 | $-30.3M | $17.1M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
